Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study

Lancet

Volumn 356, Issue 9247, 2000, Pages 2031-2036

  McKeith, Ian ^a   Del Ser, Teodoro ^b   Spano, PierFranco ^c   Emre, Murat ^d   Wesnes, Keith ^e   Anand, Ravi ^f   Cicin Sain, Ana ^f   Ferrara, Roberto ^g   Spiegel, René ^f  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b HOSPITAL SEVERO OCHOA   (Spain)

^c UNIVERSITY OF BRESCIA   (Italy)

^d ISTANBUL UNIVERSITY   (Turkey)

^e Cognitive Drug Research Ltd ^*  (United Kingdom)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Novartis Farma   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; PLACEBO; RIVASTIGMINE;

ADULT; AGED; ANOREXIA; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LEWY BODY; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TITRIMETRY; VOMITING;

EID: 0034676757     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03399-7     Document Type: Article

References (26)

1. Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
2. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
3. Consensus guidelines for the clincial and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
4. Neuroleptic sensitivity in patients with senile dementia of Lewy body type
5. Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity
6. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease
7. Lewy-body dementia and responsiveness to cholinesterase inhibitors: A paradigm for heterogeneity of Alzheimer's disease?
8. Altered consciousness and transmitter signalling in Lewy body dementia
9. Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients
10. Dementia with Lewy bodies: Response of delirium-like features to donepezil
11. Rivastigmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial
12. Lewy bodies and response to tacrine in Alzheimer's disease
13. Tacrine for senile dementia of Alzheimer's of Lewy body type
14. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
15. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
16. Mini mental state: A practical method for grading the cognitive state of patients for the clinician
17. Parkinsonism: Onset, progression and mortality
18. Members of the UPDRS development committee: Unified Parkinison's disease rating scale
19. The neuropsychiatric inventory: Comprehensive assessment of psychopathology in dementia
20. The cognitive drug research computerized assessment system for demented patients: A validation study
21. Dementia with Lewy bodies (DLB): Findings from an international multicentre study
22. Pharmacodynamic and early clinical Studies with velnacrine
23. Cholinesterase inhibitors: A new class of psychotropic compounds
24. Interrater reliability of extrapyramidal signs in a group assessed for dementia
25. Tolerability profiles of AChEIs: A Critical component of care for Alzheimer's disease patients
26. Interim results from an international clinical trial with rivastigmine evaluating a 2-week titration rate in mild to severe Alzheimer's disease patients